Market Research Report
Recombinant Drugs to 2020
|Published by||Greystone Research Associates||Product code||439381|
Delivery time: 1-2 business days
|Recombinant Drugs to 2020|
|Published: February 10, 2017||Content info:||
In recent years, the number of recombinant drugs - including engineered biological drugs in development - has increased significantly. The pace of this growth is encouraging suppliers to view competitors in new ways. Cooperation between and among drug developers and drug producers is occurring much earlier in the drug development cycle, allowing participants to improve supply chains and time-to-market. The result is a rapidly growing market sector that is changing disease therapeutics on a global scale. This report examines FDA and EMA-approved biological drugs and their position and potential in a dozen major disease segments - markets with important implications for drug developers, contract and supply chain partners and infrastructure participants. Growth prospects for key biological drug therapeutic segments will vary over the forecast period covered in this analysis, influenced by demographic, socioeconomic and competitive factors.